방사선 종양학 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 기술별, 용도별, 지역별, 부문별 예측(2025-2030년)

Radiation Oncology Market Growth & Trends:

The global radiation oncology market size is expected to reach USD 21.19 billion in 2030 and is projected to grow at a CAGR of 11.17% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the global rise in cancer burden, the growing geriatric population, and supportive reimbursement programs undertaken by the government and private organizations. Furthermore, the increasing technological innovation and advancement in radiotherapy offer lucrative opportunities for market growth.

The world is witnessing an increasing prevalence of cancer cases which is the key factor driving the radiation oncology market growth. For instance, according to Globocan, in 2020, more than 20.0 million people were diagnosed with cancer, and 10.0 million died of cancer. Moreover, the aging population is at high risk of cancer due to a weak immune system and comorbid conditions; thereby, the rising geriatric population further fuels market growth. For instance, in 2020, according to WHO estimates, the global geriatric population was approximately 1.0 billion and is expected to reach 2.1 billion by 2050.

Extensive research activities for the development of novel radiotherapy techniques and multidisciplinary therapeutic approaches are expected to lead to an increased survival rate and a more favorable prognosis of cancer. For instance, in December 2022, Elekta Unity demonstrated MR-Linac use for pancreatic tumors, where the first-ever patient was treated with new advanced radiotherapy motion management.

Similarly, in June 2020, Isoray signed a research agreement with the University of Cincinnati Physicians Company to study neck and head cancer treatment. The companies will evaluate the efficacy of Keytruda along with Cesium-131 post-surgical resection. Using such medical isotopes for cancer treatment may boost the research in developing a new target-specific radiation therapy system by understanding disease complexity & patients' need, thereby widening the opportunity in the market.

Furthermore, supportive reimbursement and regulatory policies for radiation therapy are also expected to drive the radiation oncology market growth. For instance, in July 2021, the Centers for Medicare and Medicaid Services (CMS) developed a new Radiation Oncology Payment Model (RO-APM) for the diagnosis of cancer and radiotherapy services. It enhances the quality of care of the patients and reduces the annual Medicare expenditure.

Radiation Oncology Market Report Highlights:

• The external beam radiation therapy (EBRT) market, which includes linear accelerators (Linac), and compact advanced radiotherapy systems, dominated the overall market with the largest revenue share in 2024 due to increased adoption in the treatment of various types of cancers
• The IMRT segment held the largest revenue share of 24.06% in 2024, attributed to the substantial demand for treatment and increased availability of technologically advanced intensity-modulated radiotherapy (IMRT) in countries with unmet treatment needs.
• The EBRT segment for prostate cancer held the largest revenue share of 58.65% in 2024 and is anticipated to maintain its dominance over the forecast period
• The market for IBRT is anticipated to witness significant growth over the forecast period due to the growing prevalence of cancer in developing countries and increased product penetration
• North America radiation oncology industry dominated globally in terms of revenue share of 47.16% in 2024, owing to the favorable government initiatives and availability of technologically advanced radiotherapy equipment

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Technology
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Applicationoutlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Radiation Oncology Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Rising adoption of radiotherapy
  • 3.4.2. Technological advancements in radiotherapy
  • 3.4.3. Rising prevalence of cancer
  • 3.4.4. Increase in healthcare expenditure
  • 3.4.5. Increasing application of radiopharmaceuticalsg
• 3.5. Market Restraint Analysis
  • 3.5.1. Lack Of Skilled Radiotherapy Professionals
  • 3.5.2. Inadequate Radiation Infrastructure
  • 3.5.3. Adverse Effects Of RadiotherapyType Analysis Tools
  • 3.5.4. Porter's Five Forces Analysis
  • 3.5.5. PESTEL Analysis

Chapter 4. Radiation Oncology Market: Type Estimates & Trend Analysis

• 4.1. Radiation Oncology Market: Type Movement Analysis
• 4.2. Radiation Oncology Market Estimates and Forecast, by Type
• 4.3. External Beam Radiation Therapy
  • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.3.2. Linear Accelerators (Linac)
    • 4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.3.3. Compact advanced radiotherapy systems
    • 4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.3.3.2. Cyberknife
      • 4.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.3.3.3. Gamma Knife
      • 4.3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.3.3.4. Tomotherapy
      • 4.3.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.3.4. Proton Therapy
    • 4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.3.4.2. Cyclotron
      • 4.3.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.3.4.3. Synchrotron
      • 4.3.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.4. Internal Beam Radiation Therapy
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Brachytherapy
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.2. Seeds
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.3. Applicators and After loaders
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.4. Electronic Brachytherapy
      • 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Systemic Beam Radiation Therapy
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Radiation Oncology Market: Technology Estimates & Trend Analysis

• 5.1. Radiation Oncology Market: Technology Movement Analysis
• 5.2. Radiation Oncology Market Estimates and Forecast, by Technology
• 5.3. External Beam Radiation Therapy
  • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.2. Image-Guided Radiotherapy (IGRT)
    • 5.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.3. Intensity Modulated Radiotherapy (IMRT)
    • 5.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.4. Stereotactic Technology
    • 5.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.5. Proton Beam Therapy
    • 5.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.6. 3D Conformal Radiotherapy (3D CRT)
  • 5.3.7. Volumetric Modulated Arc Therapy (VMAT)
    • 5.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.4. Brachytherapy
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Low-Dose Rate Brachytherapy
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. High-Dose Rate Brachytherapy
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Radiation Oncology Market: Application Estimates & Trend Analysis

• 6.1. Radiation Oncology Market: Application Movement Analysis
• 6.2. Radiation Oncology Market Estimates and Forecast, by End Use
• 6.3. External Beam Radiation Therapy
  • 6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Prostate Cancer
    • 6.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Breast Cancer
    • 6.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.4. Lung Cancer
    • 6.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.5. Head and Neck Cancer
    • 6.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.6. Colorectal Cancer
    • 6.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.7. Others
    • 6.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Internal Beam Radiation Therapy
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Prostate Cancer
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Breast Cancer
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Lung Cancer
    • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Head and Neck Cancer
    • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Colorectal Cancer
    • 6.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Others
    • 6.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Radiation Oncology Market: Regional Estimates & Trend Analysis

• 7.1. Radiation Oncology Market Share By Region, 2024 & 2030
• 7.2. Regional Market Share Analysis, 2024 & 2030
• 7.3. Regional Market Dashboard
• 7.4. Global Regional Market Snapshot
• 7.5. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.6. North America
  • 7.6.1. North America Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.6.2. U.S.
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. U.S. Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.6.3. Canada
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Canada Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.6.4. Mexico
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Mexico Radiation Oncology Market, 2018 - 2030 (USD Million)
• 7.7. Europe
  • 7.7.1. Europe Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.7.2. UK
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. UK Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.7.3. Germany
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Germany Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.7.4. France
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. France Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.7.5. Italy
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Italy Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.7.6. Spain
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Spain Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.7.7. Denmark
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Denmark Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.7.8. Sweden
    • 7.7.8.1. Key Country Dynamics
    • 7.7.8.2. Competitive Scenario
    • 7.7.8.3. Regulatory Framework
    • 7.7.8.4. Sweden Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.7.9. Norway
    • 7.7.9.1. Key Country Dynamics
    • 7.7.9.2. Competitive Scenario
    • 7.7.9.3. Regulatory Framework
    • 7.7.9.4. Norway Radiation Oncology Market, 2018 - 2030 (USD Million)
• 7.8. Asia Pacific
  • 7.8.1. Asia Pacific Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.8.2. Japan
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Japan Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.8.3. China
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. China Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.8.4. India
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. India Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.8.5. Australia
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Australia Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.8.6. Thailand
    • 7.8.6.1. Key Country Dynamics
    • 7.8.6.2. Competitive Scenario
    • 7.8.6.3. Regulatory Framework
    • 7.8.6.4. Thailand Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.8.7. South Korea
    • 7.8.7.1. Key Country Dynamics
    • 7.8.7.2. Competitive Scenario
    • 7.8.7.3. Regulatory Framework
    • 7.8.7.4. South Korea Radiation Oncology Market, 2018 - 2030 (USD Million)
• 7.9. Latin America
  • 7.9.1. Latin America Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.9.2. Brazil
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Competitive Scenario
    • 7.9.2.3. Regulatory Framework
    • 7.9.2.4. Brazil Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.9.3. Argentina
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Competitive Scenario
    • 7.9.3.3. Regulatory Framework
    • 7.9.3.4. Argentina Radiation Oncology Market, 2018 - 2030 (USD Million)
• 7.10. MEA
  • 7.10.1. MEA Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.10.2. South Africa
    • 7.10.2.1. Key Country Dynamics
    • 7.10.2.2. Competitive Scenario
    • 7.10.2.3. Regulatory Framework
    • 7.10.2.4. South Africa Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.10.3. Saudi Arabia
    • 7.10.3.1. Key Country Dynamics
    • 7.10.3.2. Competitive Scenario
    • 7.10.3.3. Regulatory Framework
    • 7.10.3.4. Saudi Arabia Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.10.4. UAE
    • 7.10.4.1. Key Country Dynamics
    • 7.10.4.2. Competitive Scenario
    • 7.10.4.3. Regulatory Framework
    • 7.10.4.4. UAE Radiation Oncology Market, 2018 - 2030 (USD Million)
  • 7.10.5. Kuwait
    • 7.10.5.1. Key Country Dynamics
    • 7.10.5.2. Competitive Scenario
    • 7.10.5.3. Regulatory Framework
    • 7.10.5.4. Kuwait Radiation Oncology Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company Categorization
• 8.3. Strategy Mapping
• 8.4. Company Market Share Analysis, 2024
• 8.5. Company Profiles
  • 8.5.1. Varian Medical Systems, Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Elekta AB
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Accuray Incorporated
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. IBA Radiopharma Solutions
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. BD (Becton, Dickinson and Company)
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Isoray Inc.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Mevion Medical Systems
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Nordion, Inc.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. NTP Radioisotopes SOC Ltd.
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Curium
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. ViewRay Technologies, Inc.
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic Initiatives